BIO
Bio-Rad Laboratories A
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
EPS Beats Expectation
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About BIO
Bio-Rad Laboratories, Inc.
A manufacturer of products for the life science research and clinical diagnostic markets
Life Science Tools and Services
Invalid Date
10/24/2008
New York Stock Exchange
7700
12-31
Common stock
1000 Alfred Nobel Drive, Hercules, California 94547
--
Bio-Rad Laboratories, Inc., was founded in 1952 and established as a company in 1957. It was early devoted to the research and production of specialty chemicals for use in biochemistry, pharmaceuticals and other life science research applications. It entered the field of clinical diagnostics with the development of its first technology separation suite and life science research materials. Through internal R&D efforts and decisions, it has expanded to different markets. Now, Bio-Rad offers a range of products for life science research, healthcare, analytical chemistry and other market production.
Company Financials
EPS
BIO has released its 2024 Q4 earnings. EPS was reported at 2.90, versus the expected 2.88, beating expectations. The chart below visualizes how BIO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BIO has released its 2024 Q4 earnings report, with revenue of 667.50M, reflecting a YoY change of -2.01%, and net profit of -715.80M, showing a YoY change of -304.69%. The Sankey diagram below clearly presents BIO’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
